Progyny, Inc. (PGNY)
- Previous Close
21.95 - Open
21.97 - Bid 16.08 x 200
- Ask 28.37 x 200
- Day's Range
21.92 - 22.69 - 52 Week Range
13.39 - 30.42 - Volume
1,117,133 - Avg. Volume
1,572,503 - Market Cap (intraday)
1.912B - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
39.12 - EPS (TTM)
0.57 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.25
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
www.progyny.comRecent News: PGNY
View More
Performance Overview: PGNY
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PGNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PGNY
View MoreValuation Measures
Market Cap
1.88B
Enterprise Value
1.65B
Trailing P/E
38.51
Forward P/E
14.06
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.67
Price/Book (mrq)
4.03
Enterprise Value/Revenue
1.36
Enterprise Value/EBITDA
21.54
Financial Highlights
Profitability and Income Statement
Profit Margin
4.33%
Return on Assets (ttm)
5.99%
Return on Equity (ttm)
10.11%
Revenue (ttm)
1.21B
Net Income Avi to Common (ttm)
52.5M
Diluted EPS (ttm)
0.57
Balance Sheet and Cash Flow
Total Cash (mrq)
256.12M
Total Debt/Equity (mrq)
6.19%
Levered Free Cash Flow (ttm)
200.38M
Research Analysis: PGNY
View MoreResearch Reports: PGNY
View MoreRating increased to a BUY
PROGYNY INC has an Investment Rating of BUY; a target price of $24.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetRaising target price to $25.00
PROGYNY INC has an Investment Rating of HOLD; a target price of $25.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $24.00
PROGYNY INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about PGNY?
PROGYNY INC has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target